The BioCopy technology enables further development of vaccines with regard to their effectiveness on a large number of variants, since escape variants can be identified early. We are confident that our unique vaccine mapping technology can complement Valneva’s development capabilities for various vaccines through providing a comprehensive overall picture of vaccination responses. The BioCopy technology provides in-depth data on vaccination responses against mutations, which can facilitate development of a broad spectrum vaccine in a targeted manner.
“Knowing which variants the vaccine-induced human immune response is recognizing, and adapting vaccines specifically to precisely these escape variants, has become especially important in the current pandemic,” says Günter Roth, CEO and founder of BioCopy. “However, this problem has been known for a long time and applies not only to COVID-19, but to all infectious diseases with a high mutation rate. The more broadly a vaccine is set up when it is first approved, the more time you have before the first escape variants appear.”
With BioCopy’s measurement technology, vaccine manufacturers will be put into the position to better assess the range of immune responses induced by their vaccines. The same approach should be implemented as a point-of-care in the next few years, so that every vaccinated person will be able to know the immune status and mutation resistance. Günter Roth: “We are looking forward to seeing how our technology will contribute to Valneva’s vaccine development”.